Glaucoma

Long-term results show microstent device yields stable IOP with fewer medications

Four-year postoperative results show eyes with primary open-angle glaucoma (POAG) that received Hydrus Microstent (Ivantis Inc.) combined with cataract surgery (HS) maintained a stable IOP with significantly fewer glaucoma medications compared to cataract surgery (CS), according to a poster presented at AAO 2020 Virtual. In addition, HS group eyes were...